CardiacSense News
20 articles
CardiacSense wins FDA clearance for medical-grade watch
CardiacSense has received FDA clearance for its CSF-3 medical-grade watch, which measures vital signs such as heart rate and oxygen saturation. The company plans to submit additional data to the FDA for more indications and is in discussions with prospective U.S.-based commercial partners. CardiacSense expects to launch the CSF-3 watch in the U.S. in the second half of 2023. The company has developed proprietary hardware to address motion artifacts and has demonstrated high accuracy in clinical trials. Other companies, such as Masimo, Apple, and Fitbit, have also entered the medical-grade watch market.
CustomersPartners
ניסטק תייצר 30,000 שעונים חכמים של קארדיאקסנס - Techtime - חדשות אלקטרוניקה והייטק
CardiacSense has placed an order for the production of 30,000 smart health watches from the Nistec factory in Maalot. The watches are expected to be delivered in the coming months. CardiacSense has developed a medical watch that allows continuous monitoring of heart rate and detection of arrhythmias and heart failure. The company has received marketing approval in Israel and CE approval in the European Union. It is currently working towards FDA approval. CardiacSense operates in a highly competitive market, competing with major technology corporations such as Apple, Samsung, Fitbit, and Garmin. The Nistec factory in Maalot has a unique advantage in accurately monitoring heart rate disturbances. The potential market for CardiacSenses product is estimated to be around $3 billion in the US and $10 billion worldwide.
Customers
קארדיאקסנס חברת הטכנולוגיה הרפואית מקיסריה בדרך לקבלת פטנט אירופאי על שילוב החיישנים הייחודי שלה - Chiportal
Israeli medical technology company, קארדיאקסנס, has developed a unique medical watch for remote monitoring of health indicators. The watch is based on a patented combination of optical signal reading and motion, pressure, and temperature sensors, allowing continuous tracking of vital body measurements with high accuracy. The company aims to replace expensive and invasive monitoring devices with a convenient and efficient solution that can be used anywhere. The European Patent Office has granted קארדיאקסנס a patent for their unique sensor combination, further protecting the companys technology. The development of this medical watch aligns with the global trend towards digital healthcare and remote patient monitoring.
CustomersPartners
קרדיאק-סנס החלה בשיווק השעון הרפואי. קיבלה הזמנות בהיקף של 150 מיליון דולר - Techtime - חדשות אלקטרוניקה והייטק
קרדיאק-סנס, חברת מכשור רפואי, שלחה משלוח ראשון של מאות שעונים רפואיים ללקוחות בהודו. המשלוח מסמן את תחילת המסחור של השעון הרפואי שפיתחה החברה. צבר ההזמנות שלה עומד על כ-150 מיליון דולר. החברה תפצה את השעונים בהודו על ידי המפיץ המקומי, ותספק שירותי רפואה מתקדמים בכל המדינה ללא תלות במקום או מרחק. קרדיאק-סנס פיתחה אבזר ניטור רפואי אישי המאפשר לנטר הפרעות בקצב הלב ולזהות מראש התפתחות של תופעת פרפור עליות. החברה משתמשת בא.י. אלקטרוניקה כמשקיע משקיע אסטרטגי וקיבלה ממנו תמיכה וסיוע בפיתוח המוצר, בהנדסה, בניהול שרשרת האספקה ובייצור.
CustomersInvestment
Saving lives one smartwatch at a time
Israeli medical device startup CardiacSense has developed a smartwatch that monitors heart rates and oxygen levels for patients with heart arrhythmias. The company plans to use data to predict the chances of a persons next heart attack. CardiacSenses smartwatch has obtained European regulatory clearance and plans to receive U.S. FDA approval. The company is also targeting chronic patients with heart conditions or COPD to detect early signs of deterioration and reduce rehospitalization costs. CardiacSense aims to replace expensive and uncomfortable medical-grade equipment with its smartwatch, which collects and sends data wirelessly to hospitals. The company plans to go public on the Tel Aviv Stock Exchange and is focused on raising $28 million at a $140 million valuation. CardiacSense intends to have 200,000 users by the end of next year.
Public TradingExpand
CardiacSense's medical watch was handpicked to remotely monitor vital signs and general medical condition of the Israeli Astronaut's vitals while in space
CardiacSense, a Medtech company, has been selected to send its medical watch to space to monitor the vital signs and general health condition of astronaut Eytan Stibbe during his mission to the international space station. The medical watch has already received regulatory approval and is expected to be available for commercial use soon. This project reflects the confidence in CardiacSenses technology and capabilities. The company aims to redefine telehealth and expand the limits of human and technological abilities. The Israel Aerospace Medicine Institute will collaborate on this project. CardiacSense is a Medtech company headquartered in Caesarea, Israel.
PartnersExpand
CardiacSense is set to go public on the Tel Aviv Stock Exchange
Israeli medical device company CardiacSense plans to raise NIS 90 million ($28 million) in its initial public offering on the Tel Aviv Stock Exchange. The company has developed a smartwatch that monitors heart arrhythmias and blood pressure and has received approval to distribute its product in Israel and European countries. CardiacSenses business model includes transmitting medical information in real-time to doctors and diagnosing heart arrhythmias. The company is conducting clinical trials and expects incoming revenues of $8.5 million in 2021. It employs 35 people and operates out of Caesarea, northern Israel.
InvestmentPublic TradingManagement ChangesExpand
CardiacSense Medical Grade Watch receives CE Mark for continuous detection of Atrial Fibrillation
CardiacSense, a digital health company, has received the CE Mark for its medical grade watch capable of detecting and remotely monitoring Atrial Fibrillation (A-Fib) and Heart Rate Variability (HRV). The certification allows the company to market and sell the device in the European Union. The watch eliminates the need for invasive cardiac monitors and has demonstrated accurate detection of A-Fib by continuous Photoplethysmography (PPG) of over 99%. CardiacSense has also signed $70 million distribution agreements in 15 countries and is developing its commercial strategy in major markets. The company is conducting clinical trials for additional vital signs monitoring and has submitted the watch for FDA Clearance.
CustomersPartners
קארדיאקסנס מקבוצת ההשקעות של חברת מרחביה מדווחת על סיום מוצלח של השלב הראשון בניסוי למדידת קצב נשימה בבית החולים איכילוב New-Tech OnLine
מרחביה אחזקות והשקעות (מראח) דיווחה על סיום השלב הראשון בניסוי למדידת קצב נשימה בבית החולים איכילוב. הניסוי נערך בשיתוף פעולה עם חברת קארדיאקסנס, שפיתחה שעון חכם למדידת קצב נשימה. הנתונים שנאספו בניסוי תאמו ברמה גבוהה לנתונים שנאספו באמצעות מכשיר הייחוס של החברה. קארדיאקסנס צפויה להתחיל בשלב השני של הניסוי בשבועות הקרובים.
Investment
Israeli health tech co CardiacSense teams with UAE distributor
CardiacSense, a company invested in by Merchavia Holdings and Investments Ltd., has signed a distribution agreement worth a minimum of $8 million over four years for its vital signs monitoring watch in the United Arab Emirates (UAE). The company has also signed several other distribution agreements in countries such as Switzerland, Turkey, Spain, Australia, Latin America, and South Africa. These agreements, if realized, will be worth a minimum of $70 million in the coming years. The stock price of Merchavia, which has a 5.7% stake in CardiacSense, rose following the announcement. CardiacSenses wristwatch allows for remote monitoring of body temperature and identification of conditions such as heart arrhythmia and chronic diseases. The company believes that this collaboration with a distribution company from the UAE will strengthen political ties between Israel and countries in the Persian Gulf.
CustomersPartners
מרחביה: קארדיאקסנס חתמה על הסכם הפצה בלעדי בשוויץ
CardiacSense, a company that develops and manufactures medical watches for the detection of heart rate disorders, has signed an exclusive distribution agreement with Mercury International, a Swiss medical equipment distributor. The agreement grants Mercury the responsibility for marketing and selling the watches in Switzerland, subject to obtaining CE approval. The contract is for a period of 3 years, and Mercury is obligated to meet annual purchase targets totaling approximately $2.4 million. If the distributor fails to meet the purchase targets, CardiacSense can cancel the agreement immediately. CardiacSense has also signed distribution agreements in other countries, including South America, Africa, Turkey, Northern Cyprus, Uruguay, and India. The company has recently raised $6 million in funding, with participation from Merhavia Holdings.
Partners
CardiaSense raises $6 million to mass-produce wearable health monitor
Israeli medical device developer CardiacSense Ltd. has raised $6 million in a funding round led by Together and a group of Israeli and European strategic investors. The company has developed a watch-like device that tracks factors like arrhythmia, heart rate, oxygen saturation, and blood pressure for early detection of stroke or cardiac arrest. CardiacSense claims it can significantly reduce the global cost of patient care and treatment by offering advance warning and 24/7 connectivity to medical teams. The company has agreements worth over $60 million for the marketing and distribution of its devices globally and is in the final stages of receiving FDA approval. The funding will be used for product development, clinical trials, and mass production.
InvestmentExpand
CardiacSense signs $32.4m medical watch Indian deal
Israeli medtech company CardiacSense has signed an exclusive distribution agreement in India worth at least $32.4 million. The agreement involves supplying 150,000 medical watches for use in hospitals, home hospitalizations, and monitoring chronically ill patients over the next 4 years. The distribution agreement brings CardiacSenses total backlog of orders to more than $60 million. The companys watch uses patent-protected technology to monitor vital physical measurements of patients and transmit data directly to their personal physicians. CardiacSense has also submitted the required approvals to enter into major agreements in the US and Europe. The company is responding to the growing demand for remote monitoring of diseases and the shift to online community digital healthcare.
CustomersPartners
Homestay Care (ASX:HSC) partners with CardiacSense for cardiac wearables
HomeStay Care has signed an exclusive distribution agreement with CardiacSense for its wearable vital signs monitoring products. CardiacSense manufactures medical-grade wearable devices that monitor heart activity and blood pressure. HomeStay will distribute the CardiacSense wearables and integrate the vital signs data in its uVue platform. This news follows HomeStays partnership with G Medical Innovations to integrate their products. CardiacSense wearables are undergoing certification for CE Mark in Europe and U.S. FDA approval. HomeStay is seeking TGA approval for the wearables. Shares in HomeStay Care have increased by 8.33%.
PartnersExpand
The Smartwatch That Will Warn of Cardiac Arrest Before it Occurs
CardiacSense Ltd. has developed a watch-like device that tracks factors like arrhythmia, heart rate, oxygen saturation, and blood pressure to identify early signs of stroke or cardiac arrest. The device uses ECG monitoring and PPG to send real-time data to physicians. The article highlights an interview with CardiacSenses CEO, Eldad Shemesh.
CustomersPartners
CardiacSense raises $3.5m
CardiacSense, a medical device company based in Caesarea, has completed a $3.5 million financing round, bringing its total raised amount to $8.5 million. The company has developed a smart watch for detecting heart arrhythmia, which has a level of accuracy similar to an ECG. CardiacSense has successfully completed the first of two clinical trials required by the FDA and is preparing for the second trial. The company is also developing a feature for continuous blood pressure measurement without an invasive sensor. CardiacSense has appointed two new directors, including a former executive from Pepsico and a former president of Boston Scientifics cardiology division. The company is focused on providing convenient and easy-to-use wearable medical devices for accurate and continuous measurement of essential variables.
InvestmentManagement Changes
ICYMI: CardiacSense: A New Wearable Diagnostic for AF
Israeli start-up CardiacSense is developing a smartwatch for ambulatory arrhythmia monitoring that aims to provide diagnostic results. The company is working towards FDA clearance and CE marking for its watch as a diagnostic tool for atrial fibrillation. CardiacSenses watch utilizes both PPG and ECG signals and incorporates a proprietary Artifact Sensor to address arm movement. The company has filed 10 patents and has raised nearly $5 million in funding. CardiacSense hopes to partner with a large medical device firm to bring its technology to market. The company also has a partnership with Cleveland Clinic and plans to conduct a post-market US clinical trial of the watch.
InvestmentPartners
Heart Monitoring Company CardiacSense Raises Funds to License Device
CardiacSense Ltd., a privately-held medical device company based in Israel, has raised $475,000 in funding. The company develops a watch-like device that monitors arrhythmia and blood pressure for early detection of stroke or cardiac arrest. The device uses ECG monitoring and photoplethysmography (PPG) to track patients conditions and send data to their physicians in real time. Heart diseases are the leading cause of death in the U.S., and CardiacSense aims to reduce mortality and health damages through early detection. The funding will be used to advance certifications in the U.S. and European Union, as well as conduct clinical trials and seek certification in China.
Investment
SporTracker to Unveil Next-Generation Wearable PPG Sensor
SporTracker Ltd. has announced the release of its new PPGv6 sensor for measurement of blood parameters, such as Heart Rate and Oxygen saturation. The sensor is ideal for wearable devices and offers best-in-class performance and low power consumption. It allows accurate readings over any location of the human body, even during intense activities. The PPGv6 sensor has received positive feedback from leading sport and consumer electronics companies. SporTracker aims to become a global leader in heart rate and blood parameters monitoring technology and devices.
CustomersPartners
SPO Medical in deal with Israel's SporTracker
SPO Medical Inc., a biosensor developer, has signed an MOU with SporTracker Ltd. to integrate its monitoring technology with SporTrackers products. The company targets the consumer products market, focusing on devices for sports medicine and preventing crib death. SPO Medicals technology allows for reflexive measurement of blood oxygen levels, providing differentiation from other products. The company recently scaled back its manufacturing and marketing activity and now sells its technology as a component for other companies devices. The article highlights the potential for growth in non-traditional healthcare markets and the companys unique positioning. SPO Medicals share price increased by 23% in early trading on Nasdaq. The article was published on February 9, 2010.
PartnersCustomers
